Progress Announcement
Sunflower Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company" or "this Company") announced that on March 31, 2026, during the 19th meeting of the Board of Directors, it was approved to use self-owned funds of 10 million RMB to establish Sunflower Pharmaceutical Group (Hubei) Co., Ltd. (hereinafter referred to as "Hubei Pharmaceutical Company"). Detailed information can be found in the announcement published on April 1, 2026, on the official website of the Company (www.cninfo.com.cn) regarding the investment establishment (Announcement No. 2026-019).
Investment Project Overview
Hubei Pharmaceutical Company has recently completed the registration process for enterprise establishment and obtained the business license from the Hubei Provincial Administration for Industry and Commerce, with the following details:
| Item | Details |
|---|---|
| Unified Social Credit Code | 914200607MAKAREDHX9 |
| Company Name | Sunflower Pharmaceutical Group (Hubei) Co., Ltd. |
| Registered Capital | 10 million RMB |
| Company Type | Limited liability company (non-natural person investment) |
- Establishment Date: 2026 April 13
- Legal Representative: Liu Guangqing
- Address: 128, Yuhua Road, New Technology Development Zone, Hubei Province
- Business Scope: Retail of medicines, medical devices, and other related services, including online sales and management services.
Attachments
- Business License of Sunflower Pharmaceutical Group (Hubei) Co., Ltd.